Sangamo Therapeutics(US:SGMO) ZACKS·2024-11-12 23:15Group 1 - Sangamo Therapeutics reported quarterly earnings of $0.04 per share, exceeding the Zacks Consensus Estimate of a loss of $0.03 per share, and showing a significant improvement from a loss of $0.34 per share a year ago, resulting in an earnings surprise of 233.33% [1] - The company generated revenues of $49.41 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 86.11%, compared to revenues of $9.4 million in the same quarter last year [2] - Sangamo shares have increased approximately 397% since the beginning of the year, significantly outperforming the S&P 500's gain of 25.8% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $13.85 million, and for the current fiscal year, it is -$0.51 on revenues of $27.8 million [7] - The Medical - Biomedical and Genetics industry, to which Sangamo belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] Group 3 - The estimate revisions trend for Sangamo is mixed, leading to a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6] - Another company in the same industry, Mersana Therapeutics, is expected to report a quarterly loss of $0.18 per share, reflecting a year-over-year change of +48.6%, with revenues anticipated to be $9.49 million, up 23.2% from the previous year [9][10]